/
rYojbaba Co., Ltd. is a Japanese service company focused on improving and restoring physical and mental health affected by work-related stress. Headquartered in Fukuoka and founded in 2015, the company operates through two main segments: Labor Consulting Services and Health Services. The Labor Consulting Services segment provides labor and corporate consulting aimed at fostering constructive employment relationships between companies and their employees, including support on workplace practices, compliance, and organizational well-being. The Health Services segment delivers hands-on care through osteopathic clinics and osteopathic beauty salons, targeting musculoskeletal issues, stress-related discomfort, and overall physical conditioning. By combining organizational consulting with direct health interventions, rYojbaba Co., Ltd. serves corporate clients and individual patients seeking structured approaches to workplace health challenges. Its role in the market centers on bridging human resources consulting with practical healthcare solutions tailored to modern work environments in Japan.
$4.20
$0.18 (-4.11%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-8.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 19.4% YoY. Margins deteriorated 24.2pp alongside, both lines moving the wrong way.
ROIC dropped from 8.91% to -4.25%, capital efficiency is deteriorating. Net debt of $3M represents 4.3x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
▼ -19.4% YoY
Net Income (TTM)
$119K
▼ -91.0% YoY
Op. Margin
-8.09%
▼ -24.2pp YoY
ROIC
-4.25%
▼ -13.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$688K
▲ +1.1% YoY
Op. Cash Flow (TTM)
$1M
▲ +59.8% YoY
Net Debt
$3M
Cash & Equiv.
$6M
Continue Research
rYojbaba Co. (RYOJ) trades below a two-stage DCF intrinsic value of about $138.79 per share, so at $4.20 the stock looks undervalued (3,204.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, rYojbaba Co. scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $138.79 per share for RYOJ, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $104.09. At today's $4.20, that puts the stock about 3,204.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
rYojbaba Co. scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -8.1% operating margin and a -4.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. RYOJ currently trades below its estimated intrinsic value and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.